Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price fell 23.5% during mid-day trading on Saturday . The stock traded as low as C$0.09 and last traded at C$0.13. 119,000 shares were traded during mid-day trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Down 23.5%
The firm’s 50-day moving average price is C$0.16 and its 200-day moving average price is C$0.17. The company has a market cap of C$19.27 million, a price-to-earnings ratio of -4.64 and a beta of 0.67. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- What is a SEC Filing?
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- Are Penny Stocks a Good Fit for Your Portfolio?
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
